Posted inNews and Updates
Argenx Vyvgart Hits Key Phase 3 Goal in Myositis Trial
Argenx reports successful Phase 3 trial results for Vyvgart in treating autoimmune myositis, marking a major milestone for this targeted FcRn inhibitor.
Posted inNews and Updates
Aurobindo Pharma Clears FDA Review for US Facility
Aurobindo Pharma shares rise 2% after clearing a rigorous USFDA inspection. Learn how this regulatory success impacts the company's manufacturing outlook.
Posted inNews and Updates
Can Low-Level Laser Therapy Improve Dental Implants?
New research explores how Low-Level Laser Therapy (LLLT) accelerates dental implant osseointegration and improves peri-implant clinical health outcomes.
Posted inNews and Updates
July 2026 Clinical Trial Pipeline: Key Growth Trends
Explore the July 2026 clinical trial recruiting trends. Learn how protocol design, AI, and patient-centric strategies are shaping the future of enrollment.
Posted inNews and Updates
US FDA Issues VAI Classification for Aurobindo Raleigh Unit
The US FDA has granted a Voluntary Action Indicated (VAI) status to Aurobindo Pharma's Raleigh unit. Learn what this classification means for the facility.
Posted inNews and Updates
Can Lidocaine Reduce Inflammation After Heart Bypass?
Researchers are testing if lidocaine can lower inflammation after heart bypass surgery. Discover how this common drug may reduce post-op risks.
Posted inNews and Updates
AbelZeta Regains C-CAR039 Rights; FDA Greenlights Trial
AbelZeta regains global rights to C-CAR039 and receives FDA IND clearance for trials in Large B-cell Lymphoma, marking a major step in CAR-T innovation.
Posted inNews and Updates
ArkBio Initiates US Phase II Trial for RSV Drug Ziresovir
ArkBio has launched a US Phase II trial for Ziresovir, a novel antiviral treatment targeting severe RSV in infants. Discover the potential clinical impact.
Posted inNews and Updates
The AI Validation Gap: Are Clinical Tools Moving Too Fast?
Are AI decision support tools moving faster than the evidence? Explore the critical validation gap threatening patient safety in modern clinical settings.
Posted inNews and Updates
Aizen Therapeutics Secures $100M Deal for Peptide Research
San Diego’s Aizen Therapeutics secures a $100M-per-target deal to pioneer innovative peptide-based drugs. Discover what this means for precision medicine.